Covid-19: vaccine mixing with positive effects on immune response

According to data from the analysis of antibody levels, of the 1905 people vaccinated and monitored in the study carried out by Instituto Gulbenkian de Ciência, those who followed a mixed vaccination scheme, with the first dose of Oxford/AstraZeneca and the second dose of Pfizer/BioNTech, generated a greater number of antibodies compared to the two doses of Oxford/AstraZeneca vaccine. The data also revealed that the levels of antibodies, after the two doses of the Pfizer/BioNTech vaccine, were higher than those generated with other vaccination schemes.

Check the latest news in the press about the study (in Portuguese):

in Expresso

in RTP

Updated on 27 december 2021

Cookies settings

Cookies Selection

The Calouste Gulbenkian Foundation uses cookies to improve your browsing experience, security, and its website performance. The Foundation may also use cookies to share information on social media and to display messages and advertisements personalised to your interests, both on our website and in others.